M

Medication Management | Greensboro - Cardiology

Research site
(Unclaimed)
Location
1910-A North Church Street, Greensboro, North Carolina, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

21 of 67
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Chronic Weight Management Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling
Overweight
Obesity
Drug: LY3305677
Drug: LY3841136

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting
Psoriatic Arthritis
Biological: Risankizumab
Biological: Placebo

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectom...

Active, not recruiting
Prostatic Neoplasms
Drug: Placebo
Drug: Apalutamide

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Enrolling
Rheumatoid Arthritis
Drug: Baricitinib
Drug: TNF Inhibitor

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Placebo in 1.5ml
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safet...

Enrolling
Overweight and Obesity
Obesity
Drug: LY3841136
Drug: Placebo

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: BIIB059 (litifilimab)
Drug: Placebo

The primary objective of this study is to evaluate the long-term safety and tolerability of litifilimab in participants with active systemic lupus er...

Invitation-only
Systemic Lupus Erythematosus (SLE)
Drug: Litifilimab-matching placebo
Drug: Litifilimab

Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evalu...

Active, not recruiting
Eosinophilic Esophagitis
Drug: CC-93538
Other: Placebo

The primary objective of this study is to demonstrate efficacy of litifilimab (BIIB059) compared with placebo in participants with active systemic lu...

Enrolling
Lupus Erythematosus, Systemic
Drug: Litifilimab
Drug: Placebo

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Enrolling
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Obicetrapib

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and...

Enrolling
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Retatrutide

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

The primary objective of this study is to collect sensor data from insertable cardiac monitor systems.

Enrolling
Heart Failure
Device: Investigational LUX-Dx ICM Implant
Locations recently updated

This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with gi...

Enrolling
Giant Cell Arteritis (GCA)
Biological: Secukinumab 150 mg
Other: Placebo

This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will e...

Enrolling
Eosinophilic Esophagitis
Drug: CC-93538

The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will initially r...

Active, not recruiting
Mixed Dyslipidemia
Drug: Placebo
Drug: ARO-ANG3

This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduc...

Enrolling
Reduced Ejection Fraction
Heart Failure
Drug: INL1
Other: Placebo

Trial conditions

Arthritis (15 trials)
Rheumatoid Arthritis (14 trials)
Systemic Lupus Erythemat... (8 trials)
Cardiovascular Diseases (5 trials)
Diabetes Mellitus (5 trials)
Heart Failure (4 trials)
Atherosclerosis (3 trials)
Atopic Dermatitis (3 trials)
Colorectal Cancer (3 trials)
Dermatitis (3 trials)

And 53 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems